Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS
申请人:BROWN Dennis M.
公开号:US20160067241A1
公开(公告)日:2016-03-10
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to naphthalimides such as amonafide or analogs, derivatives, or prodrugs thereof.
US8906916B2
申请人:——
公开号:US8906916B2
公开(公告)日:2014-12-09
[DE] PYRIMIDINDERIVATE ALS FAK INHIBITOREN<br/>[EN] PYRIMIDINE DERIVATIVES AS FAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE EN TANT QU'INHIBITEURS DE FAK
申请人:MERCK PATENT GMBH
公开号:WO2012022408A1
公开(公告)日:2012-02-23
Verbindungen der Formel (I), worin R1, R2 und R3 die in Anspruch 1 angegebenen Bedeutungen haben, sind Kinase-Inhibitoren und können u.a. zur Behandlung von Tumoren eingesetzt werden.